Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

Achhra, Amit C; Mocroft, Amanda; Ross, Michael; Ryom-Nielson, Lene; Avihingsanon, Anchalee; Bakowska, Elzbieta; Belloso, Waldo; Clarke, Amanda; Furrer, Hansjakob; Lucas, Gregory M; Ristola, Matti; Rassool, Mohammed; Ross, Jonathan; Somboonwit, Charurut; Sharma, Shweta; Wyatt, Christina (2017). Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. International journal of antimicrobial agents, 50(3), pp. 453-460. Elsevier 10.1016/j.ijantimicag.2017.04.021

Preview	Text 1-s2.0-S0924857917302303-main.pdf - Accepted Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview
	Text 1-s2.0-S0924857917302303-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (916kB)

BACKGROUND

Both untreated HIV infection and antiretroviral therapy (ART) have been associated with worsening kidney function. The impact of earlier ART initiation on kidney function has not been studied.

METHODS

The START trial was a randomized comparison of immediate versus deferred ART initiation among HIV+ persons with CD4+ counts >500 cells/mm(3). Serum creatinine and urine dipstick protein were measured at baseline, months 1, 4, 8, 12, and annually thereafter. We compared the two arms for changes in estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) over time using longitudinal mixed models.

FINDINGS

Of 4685 START participants, 4629 (n=2294 in immediate and 2335 in deferred arm) individuals were included. Median baseline CD4 and eGFR were 651 cells/mm(3) and 111⋅5 mL/min/1⋅73m(2). ART was initiated in 2271 participants (99%) in the immediate and 1127 participants (48%) in the deferred arm, accounting for over 94% and 19% of follow-up time, respectively. Overall, 89% started ART using a tenofovir-based regimen. Over a median follow-up of 2⋅1 years, the mean eGFR was 0⋅56 (95% CI: 0⋅003-1⋅11) mL/min/1⋅73m(2) higher in the immediate arm than the deferred arm. This difference was more prominent after adjustment for current use of tenofovir or boosted-protease inhibitors (1⋅85, 95% CI: 1⋅21-2⋅50), and was more prominent in participants of black race (30% overall) (3⋅90, 95% CI: 2⋅84-4⋅97) compared to non-black (1⋅05, 95% CI: 0⋅33-1⋅77) (p<0⋅001 for interaction). Relative risk for proteinuria in the immediate vs. deferred arm was 0⋅74 (95% CI: 0⋅55-1⋅00), P=0⋅049. The incidence of chronic kidney disease as defined by eGFR < 60 or dipstick proteinuria was low, and there was no significant difference between treatment arms (incidence rate ratio 0.79, 95% CI 0.59-1.05).

CONCLUSION

In the short-term, immediate ART initiation was associated with a modestly higher eGFR and lower risk of proteinuria as opposed to deferring ART- a difference more pronounced in those with black race. Whether this early benefit translates into a lower risk of chronic kidney disease requires further follow-up.

Interest & Impact

Downloads

244 since deposited on 07 Nov 2017
31 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item